Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pfizer (PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 revenue guidance of $61 billion to ...

Company rebuilding following decline in demand for its covid products, slashing about €6.2bn from its spending and focusing ...

Pfizer is starting to execute on its turnaround plan and drug pipeline. 10 stocks we like better than Pfizer › Shares of the ...

Aug 5 - Pfizer (NYSE:PFE) released its Q2 earnings amid growing investor caution. Pfizer's revenue rose 10% to $14.7 billion, ...